STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- In Elekta's second quarter, we managed to perform better than the overall radiotherapy market both in terms of orders and revenue despite continuous challenging circumstances. We also improved margins and stabilized cash flow. The launch of our new Harmony linac and regulatory clearances enhanced our product portfolio and strengthened our ability to deliver on our strategy of Precision Radiation Medicine.
Gustaf Salford President and CEO
Second quarter
Covid-19 continued to have a negative impact on Elekta's growth in the quarter
Gross order intake amounted to SEK 3,627 M (4,036), corresponding to a 2 percent decrease in constant currency
Net sales were SEK 3,534 M (3,709), corresponding to a 3 percent growth in constant currency
Gross margin amounted to 40.9 (41.0) percent
EBITA increased by 39 percent to SEK 752 M (539), corresponding to an EBITA margin of 21.3 percent (14.5)
Earnings per share was SEK 0.98 (0.58) before/after dilution
Cash flow after continuous investments improved by SEK 128 M to SEK 362 M (234)
Launch of a new linac solution, Harmony
First six months
Gross order intake amounted to SEK 8,078 M (8,426), corresponding to a 1 percent growth in constant currency
Net sales were SEK 6,515 M (6,937), corresponding to a 1 percent decrease in constant currency
Gross margin amounted to 43.2 (41.7) percent
EBITA amounted to SEK 1,303 M (987), corresponding to an EBITA margin of 20.0 percent (14.2)
Earnings per share was SEK 1.55 (0.96) before/after dilution
Cash flow after continuous investments improved by SEK 939 M to SEK 389 M (-550)
Significant events after the quarter
The Board of Director has appointed Gustaf Salford as Elekta's President and CEO with immediate effect.
Introduction of Elekta Studio with the ImagingRing providing a complete image-guided brachytherapy workflow to a single room.
1 After continuous investments. 2 Before / after dilution. 3 Based on constant currency.
For further information, please contact: Cecilia Ketels, Head of Investor Relations Tel: +46 76 611 76 25, e-mail: [email protected] Time zone: CET: Central European Time
Johan Adebäck, Acting CFO, Elekta AB (publ) Tel: +46 70 873 33 21, e-mail: [email protected] Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 26, 2020. (REGMAR)
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
NanoViricides, Inc. (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, will be attending the EF Hutton Annual Global...
Allied Market Research published a report, titled, "Travel Insurance Market by Insurance Cover (Single-Trip Travel Insurance, Annual Multi-Trip Travel Insurance, and Long-Stay Travel Insurance), Distribution Channel...
Li-Cycle Holdings Corp. ("Li-Cycle" or the "Company"), a leading global lithium-ion battery resource recovery company, today announced financial results and business updates for its first quarter ended March 31, 2024.
"During the first quarter of...
AngloGold Ashanti plc ("AngloGold Ashanti", "AGA" or the "Company") today reported a 2% year-on-year increase in first quarter gold production1, in line with its plans and despite the previously reported impact of rains and flooding in Western...
CBAK Energy Technology, Inc. ("CBAK Energy," or the "Company") a leading lithium-ion battery manufacturer and electric energy solution provider in China, today reported its unaudited financial results for the first quarter ended March 31, 2024....